licensing
Lilly revives ImmunoGen ADC pact with new $1.7bn deal
Phil Taylor
antibody-drug conjugate, Eli Lilly, immunogen, licensing, Oncology, partnering
0 Comment
GSK aims at NASH target with $1bn-plus Arrowhead alliance
Phil Taylor
Arrowhead Pharmaceuticals, GlaxoSmithKline, licensing, NASH, partnering
0 Comment
Lilly taps Lycia for protein degrader tech in $1.6bn deal
Phil Taylor
Eli Lilly, immunology, licensing, Lycia Therapeutics, pain, partnering, protein degradation
0 Comment
Akili adds to ADHD gaming range with $37.5m TALi licensing deal
Phil Taylor
Akili, attention deficit hyperactivity disorder, digital, digital health, digital therapeutics, licensing, TALi
0 Comment
Amgen pays Kyowa $400m upfront for OX40 eczema drug
Phil Taylor
Amgen, atopic dermatitis, dermatology, Dupixent, Kyowa Kirin, licensing, OX40, Regeneron, Sanofi
0 Comment
Biogen bolsters ischaemic stroke pipeline with thrombolytic from TMS
Phil Taylor
Biogen, central nervous system, licensing, stroke, thrombolysis
0 Comment
Merck KGaA offloads failed MEK programme to startup Day One
Phil Taylor
brain cancer, Day One Biopharmaceuticals, licensing, Merck KGaA, Oncology
0 Comment
Lilly adds to pain pipeline with Asahi Kasei licensing deal
Phil Taylor
Asahi Kasei, Eli Lilly, licensing, Neuropathic pain, pain
0 Comment